Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry.

This study looked at how effective and safe a drug called eptinezumab is for migraine patients in real life. The research involved 302 patients from a French hospital registry. Most of the patients were women, and their average age was about 48 years. These patients suffered from difficult-to-treat migraines and had tried at least three other treatments without success. Many of them experienced chronic migraines or episodic migraines. A significant number also had issues with medication overuse. After receiving eptinezumab, the researchers measured how many patients reported a reduction in their migraine days. The study aimed to see if eptinezumab could help these patients who had not previously used CGRP monoclonal antibodies. Overall, the findings suggest that eptinezumab may be an effective option for those struggling with this condition in everyday settings. Clinical relevance: This research indicates that eptinezumab may provide effective relief for patients with difficult-to-treat migraines, enhancing treatment options for those who have not responded to other therapies.